We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
THE LEE COMPANY

BRAHMS GMBH

BRAHMS GmbH, a Thermo Fisher Scientific company, develops and manufactures diagnostic test procedures for improving t... read more Featured Products: More products

Download Mobile App





Cytokine Signature Identifies COVID-19 Patients With Worst Prognosis

By LabMedica International staff writers
Posted on 27 Apr 2022
Print article
Image: The Ella Automated Immunoassay System (Photo courtesy of R&D Systems)
Image: The Ella Automated Immunoassay System (Photo courtesy of R&D Systems)

An overreaction of the immune system, in which excessive levels of proteins called cytokines produce damaging levels of inflammation, can lead to organ failure and death in COVID-19 patients.

It isn’t known, however, which cytokines drive the process. The ability to measure levels of these cytokines when patients are admitted to the hospital would allow those with the worst prognosis to be identified and their therapy personalized.

Laboratory Medicine specialists at the Azienda Sanitaria Universitaria Friuli Centrale (Udine, Italy) carried out a retrospective study of 415 patients (65.5% male) hospitalized with COVID-19 between May 2020 and March 2021. The cohort included patients with disease of all levels of severity. The patients, who had an average age of 70 years, were classified as having mild/moderate disease or severe/critical disease, according to the World Health Organisation definition. Death occurred in 15.7% of the patients who died in hospital and 23.6% had a negative outcome (orotracheal intubation and/or death).

Serum levels of a large panel of cytokines were measured on admission and compared against outcomes, in combination with other biomarkers such as C-reactive protein (CRP) and mid regional pro-adrenomedullin (MR-proADM). MR-proADM plasma concentrations were measured in an automated Kryptor analyzer, using TRACE technology (Kryptor; BRAHMS, Hennigsdorf, Germany). Cytokines were measured by microfluidic ultrasensitive ELISA using the Protein simple plex technology on an Ella Automated Immunoassay System instrument (R&D Systems, Minneapolis, MN, USA).

The team was able to build a decision tree that allowed them to predict those at risk of a negative outcome, based on the levels of the cytokines and other biomarkers in their blood. This first split patients into two groups, based on their IL-6 levels, before using their levels of IL-10, MR-proADM, sIL2Ra, IP10, and CRP to determine whether they were at risk of a negative outcome.

The analysis also revealed that high levels of interferon (IFN)-γ inducible protein (IP-10) on admission can signal an excessive immune response that may lead to the patient developing lung fibrosis and needing intubation. A further finding was that high levels of IL-6, a pro-inflammatory cytokine, can be accompanied by elevated levels of sIL2Ra and IL-10, which have an anti-inflammatory role. This is important, because in such cases, the immunosuppressive drugs normally used to treat severe COVID could do more harm than good.

Emanuela Sozio, MD, an Infectious Disease specialist and lead author of the study, said, “It is not always possible to determine which COVID-19 patients have the worst prognosis, especially early on. It is becoming increasingly clear, however, that the earlier we treat excessive inflammation, the more likely we are to turn it off quickly and definitively and so avoid irreversible organ damage. Our work may help select patients with worse prognoses that need to be admitted to high dependency units, as well as potentially help personalize their treatment.” The study was presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), held in Lisbon, Portugal, 23-26 April, 2022.

Related Links:
Azienda Sanitaria Universitaria Friuli Centrale
BRAHMS 
R&D Systems 

Platinum Supplier
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Gold Supplier
Blood Ammonia Test Analyzer
DRI-CHEM NX10N
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
H. pylori Test
QuickVue H. pylori Test

Print article

Channels

Clinical Chemistry

view channel
Image: A module with eight micro-devices, complete with microfluidic channels and drive motors (Photo courtesy of U.S Department of Energy)

Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses

Understanding the acidity or alkalinity of substances through pH measurement is crucial in many fields, from environmental monitoring to healthcare product safety. In many cases, these measurements must... Read more

Molecular Diagnostics

view channel
Image: The PrismRA blood test helps target best treatments for patients with rheumatoid arthritis (Photo courtesy of Scipher Medicine)

Groundbreaking Rheumatoid Arthritis Blood Test Predicts Treatment Response

Rheumatoid arthritis (RA), an autoimmune disease affecting joints and other systems in the body, impacts millions globally. Typically, the initial biologic treatment involves anti-inflammatory drugs from... Read more

Hematology

view channel
Image: The QScout hematology analyzer has received US FDA 510(k) clearance (Photo courtesy of Ad Astra Diagnostics)

First Rapid-Result Hematology Analyzer Reports Measures of Infection and Severity at POC

Sepsis, a critical medical condition that arises as an extreme response to infection, poses a significant health threat. It occurs when an infection triggers a widespread inflammatory response in the body.... Read more

Microbiology

view channel
Image: Current testing methods for antibiotic susceptibility rely on growing bacterial colonies in the presence of antibiotics (Photo courtesy of 123RF)

Rapid Antimicrobial Susceptibility Test Returns Results within 30 Minutes

In 2019, antimicrobial resistance (AMR) was responsible for the deaths of approximately 1.3 million individuals. The conventional approach for testing antimicrobial susceptibility involves cultivating... Read more

Pathology

view channel
Image: AI methods used in satellite imaging can help researchers analyze tumor images (Photo courtesy of Karolinska Institutet)

AI Approach Combines Satellite Imaging and Ecology Techniques for Analysis of Tumor Tissue

Advancements in tumor imaging technology have significantly enhanced our ability to observe the minute details of tumors, but this also brings the challenge of interpreting vast amounts of data generated... Read more

Industry

view channel
Image: The acquisition significantly expands Medix Biochemica’s portfolio of IVD raw materials (Photo courtesy of ViroStat)

Medix Biochemica Acquires US-Based ViroStat to Expand Infectious Diseases Antibody Offering

Medix Biochemica (Espoo, Finland), a supplier of critical raw materials to the in vitro diagnostics (IVD) industry, has acquired ViroStat LLC (Portland, ME, USA), a provider of infectious disease antibodies... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.